ImmunoCellular Plans Job Cuts in Shift to Stem-to-T-Cell Program

05:45 EDT 24 Aug 2017 | Genetic Engineering News

Two months after winding down development of its lead candidate for lack of funds, ImmunoCellular Therapeutics says it will cut jobs and facilities in a restructuring designed to lower costs and refocus the company on its program to generate cancer-killing T cells by engineering hematopoietic stem cells. The company gave no details on how many jobs will be eliminated, or which facilities would be jettisoned in a statement yesterday. ImmunoCellular has seven full-time and two part-time employees, according to its Form 10-Q for the second quarter, filed August 14. “The board and management of ImmunoCellular remain committed to pursuing a viable strategic path forward for the Company, with the goal of realizing the value of our immuno-oncology technology platform and assets,” stated ImmunoCellular President and CEO Anthony J. Gringeri, Ph.D. To that end, ImmunoCellular said, it will shift its attention to developing its “Stem-to-T-Cell” research program, ...

Original Article: ImmunoCellular Plans Job Cuts in Shift to Stem-to-T-Cell Program


More From BioPortfolio on "ImmunoCellular Plans Job Cuts in Shift to Stem-to-T-Cell Program"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...